Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tranexamic acid · 1 trial · 8 indications
measured by the number of eligible patients and number that consent to the study intervention
Patient triage time will be compared to time consent was obtained
all participants will have consent and intervention time documented
| Arm | Type | Description |
|---|---|---|
| Intervention- TXA | EXPERIMENTAL | Drug: one-time intravesical administration of 1gm of TXA instilled via urinary catheter, instilled for 15min before continuous bladder irrigation treatment beings. 1gm of TXA will be mixed with 100cc NS |
| Name | Type | Description |
|---|---|---|
| Tranexamic acid | DRUG | 1gm instilled instravesically |
Inclusion Criteria: * 18 years of age or older * complaint of hematuria or urinary retention * requiring CBI treatment * able to consent to the study. Exclusion Criteria: * Pregnancy or breastfeeding * Use of anticoagulants (warfarin, heparin, DOACs, etc.) * known coagulopathy (genetic bleeding d...
Tranexamic acid is being studied for use in urologic diseases, specifically for patients with hematuria and clot retention. It is an investigational small molecule in Phase 1 clinical development. The completed trial enrolled 14 participants with conditions including prostate cancer, bladder cancer, urinary retention, and hematuria.
Tranexamic acid is an antifibrinolytic agent, meaning it works by inhibiting fibrinolysis, the process that breaks down blood clots. This mechanism helps stabilize clots and reduce bleeding. In the context of the clinical trial, it is administered intravesically, directly into the bladder, to manage hematuria and clot retention.
Tranexamic acid is being developed by Smith & Nephew SNATS, Inc., a subsidiary of Smith & Nephew plc, which trades under the ticker SNN. The company is conducting clinical research on this drug for urologic indications, specifically targeting hematuria and clot retention in patients with urologic diseases.
Tranexamic acid is in Phase 1 clinical development. The single clinical trial for this drug, NCT04555343, has been completed. It is an investigational drug and has not been approved by regulatory authorities for the studied indication. The trial was uncontrolled, non-randomized, and not double-blinded.
Tranexamic acid has one completed clinical trial, NCT04555343, titled 'Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention.' This Phase 1 study enrolled 14 participants in Canada, aged 18 years and older, and included both males and females. The trial was uncontrolled and did not use randomization or blinding.
Tranexamic acid is a specific antifibrinolytic agent. While it shares a mechanism with other drugs in its class, such as aminocaproic acid, it is a distinct chemical entity. The clinical trial data provided does not indicate any alternative names for this drug, so it is referred to solely as tranexamic acid.